TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06904235: A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing

Sponsor: Helsinn Healthcare SA · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 95 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,035,800

Rescue Site Savings

+$3,326,400

Unlock Full NCT06904235 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06904235 Rescue Dossier →